Full Press Release Details
Pharmaceuticals to Present at the 2016 BIO Investor Forum in San
Francisco on October 18, 2016
VICTORIA, British Columbia--(BUSINESS WIRE)--October 11, 2016--Aurinia
Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its
Chief Executive Officer, Charles Rowland, will present a corporate
overview of the Company at the 2016 BIO Investor Forum, taking place
October 18-19 at the Westin St. Francis in San Francisco. The
presentation will also be available via webcast at the link listed below.
Aurinia Presentation Details
Date: Tuesday, October 18th
Location: Westin St. Francis Hotel
Aurinia is a clinical stage biopharmaceutical company focused on
developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high unmet
medical need. The company is currently developing voclosporin, an
investigational drug, for the treatment of lupus nephritis (LN), in an
inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE)
and represents a serious progression of SLE. The company is
headquartered in Victoria, BC and focuses its development efforts
Visit www.auriniapharma.com for more information.
Investor & Media Contact:
VP, Investor Relations